[go: up one dir, main page]

MA34726B1 - Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3 - Google Patents

Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3

Info

Publication number
MA34726B1
MA34726B1 MA35999A MA35999A MA34726B1 MA 34726 B1 MA34726 B1 MA 34726B1 MA 35999 A MA35999 A MA 35999A MA 35999 A MA35999 A MA 35999A MA 34726 B1 MA34726 B1 MA 34726B1
Authority
MA
Morocco
Prior art keywords
side effects
effects caused
specific
preventing side
linkage domains
Prior art date
Application number
MA35999A
Other languages
English (en)
Inventor
Dirk Nagorsen
Juergen Scheele
Gerhard Zugmaier
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45044532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34726(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of MA34726B1 publication Critical patent/MA34726B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

L'invention concerne un glucocorticoïde (GC) s'utilisant dans l'amélioration, le traitement thérapeutique ou prophylactique d'effets secondaires neurologiques/psychiatriques provoqués par un domaine de liaison de CD3. Elle concerne aussi des trousses comprenant un GC, un domaine de liaison de CD3 et un mode d'emploi qui indique que le GC est destiné à être utilisé pour traiter, améliorer et/ou traiter de manière prophylactique des effets secondaires provoqués par un domaine de liaison de CD3.
MA35999A 2010-11-10 2013-06-10 Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3 MA34726B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41222910P 2010-11-10 2010-11-10
PCT/EP2011/068862 WO2012062596A1 (fr) 2010-11-10 2011-10-27 Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3

Publications (1)

Publication Number Publication Date
MA34726B1 true MA34726B1 (fr) 2013-12-03

Family

ID=45044532

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35999A MA34726B1 (fr) 2010-11-10 2013-06-10 Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3

Country Status (32)

Country Link
US (2) US10130638B2 (fr)
EP (3) EP3228315B1 (fr)
JP (2) JP6023717B2 (fr)
KR (1) KR101891845B1 (fr)
CN (2) CN103533943B (fr)
AU (3) AU2011328393B2 (fr)
CA (1) CA2816668C (fr)
CL (1) CL2013001287A1 (fr)
CR (1) CR20130278A (fr)
CY (1) CY1118894T1 (fr)
DK (1) DK2637670T4 (fr)
EA (1) EA026075B1 (fr)
ES (2) ES2627538T5 (fr)
FI (1) FI2637670T4 (fr)
HR (1) HRP20170814T4 (fr)
HU (1) HUE032782T2 (fr)
IL (2) IL226268B (fr)
LT (1) LT2637670T (fr)
MA (1) MA34726B1 (fr)
ME (1) ME02722B (fr)
MY (1) MY173177A (fr)
NZ (1) NZ610034A (fr)
PH (1) PH12013500940A1 (fr)
PL (1) PL2637670T5 (fr)
PT (1) PT2637670T (fr)
RS (1) RS55995B2 (fr)
SG (2) SG190174A1 (fr)
SI (1) SI2637670T2 (fr)
SM (1) SMT201700250T1 (fr)
TN (1) TN2013000250A1 (fr)
UA (1) UA113397C2 (fr)
WO (1) WO2012062596A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874821B1 (fr) 2005-04-26 2013-04-17 Trion Pharma Gmbh Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer
KR101891845B1 (ko) 2010-11-10 2018-08-24 암젠 리서치 (뮌헨) 게엠베하 Cd3-특이적 결합 도메인에 의해 유발된 악영향의 예방
EP3753572A1 (fr) * 2011-04-28 2020-12-23 Amgen Research (Munich) GmbH Régime posologique pour l'administration d'un anticorps bispécifique cd19xcd3 à des patients à risque d'éventuels effets indésirables
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP3421495A3 (fr) 2013-03-15 2019-05-15 Xencor, Inc. Modulation de cellules t avec des anticorps bispécifiques et des fusions fc
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CN111138543B (zh) * 2013-03-15 2024-06-11 Xencor股份有限公司 异二聚体蛋白
EP3192812B1 (fr) 2013-12-17 2020-05-27 Genentech, Inc. Anticorps anti-cd3 et leurs utilisations
LT3122781T (lt) 2014-03-28 2020-03-25 Xencor, Inc. Bispecifiniai antikūnai, kurie jungiasi prie cd38 ir cd3
BR112017004802A2 (pt) 2014-09-12 2017-12-12 Genentech Inc anticorpos anti-cll-1 e imunoconjugados
TN2017000223A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
IL252467B (en) 2014-11-26 2022-06-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
PT3227336T (pt) 2014-12-05 2019-09-09 Hoffmann La Roche Anticorpos anti-cd79b e métodos de utilização
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
HUE063270T2 (hu) 2015-06-16 2024-01-28 Hoffmann La Roche Az FcRH5 elleni humanizált és affinitásérett antitestek és alkalmazási eljárások
EP3310378B1 (fr) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anticorps anti-c1 et leurs procédés d'utilisation
CN108137706A (zh) 2015-07-15 2018-06-08 酵活有限公司 药物缀合的双特异性抗原结合构建体
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CN106810610A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
MA43959A (fr) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
MA45255A (fr) 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
CA3029328A1 (fr) 2016-06-28 2018-01-04 Xencor, Inc. Anticorps heterodimeriques qui se lient au recepteur 2 de la somatostatine
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7142630B2 (ja) 2016-10-14 2022-09-27 ゼンコア インコーポレイテッド ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質
CA3042435A1 (fr) 2016-11-15 2018-05-24 Genentech, Inc. Dosage pour le traitement avec des anticorps bispecifiques anti-cd20/anti-cd3
MA46963A (fr) * 2016-12-03 2019-10-09 Juno Therapeutics Inc Méthodes pour déterminer le dosage de céllules car-t
KR20180090600A (ko) 2017-02-03 2018-08-13 주식회사 대유위니아 전기밥솥
EP4353818A3 (fr) 2017-02-27 2024-06-19 Juno Therapeutics, Inc. Compositions, articles manufacturés et procédés associés au dosage en thérapie cellulaire
EP3409322A1 (fr) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Procédés de traitement
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
WO2019046233A1 (fr) * 2017-08-30 2019-03-07 Bristol-Myers Squibb Company Procédé de surveillance de réponses pharmacodynamiques médiées par l'administration in vivo de glucocorticoïdes
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
CA3097741A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
KR20250156861A (ko) 2019-05-21 2025-11-03 노파르티스 아게 Cd19 결합 분자 및 이의 용도
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
EP4072584B1 (fr) 2019-12-13 2026-01-28 Genentech, Inc. Anti-ly6g6d anticorps et methodes pour utilisation
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3182445A1 (fr) 2020-06-11 2021-12-16 Francisco Leon Procedes et compositions de prevention du diabete de type 1
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
CA3196539A1 (fr) 2020-11-04 2022-05-12 Chi-Chung Li Dosage pour le traitement avec des anticorps bispecifiques anti-cd20/anti-cd3
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
WO2022216702A1 (fr) * 2021-04-06 2022-10-13 Memorial Sloan-Kettering Cancer Center Polythérapie avec dexaméthasone et lymphocytes t spécifiques d'une tumeur mettant en contact des anticorps multispécifiques pour le traitement du cancer
BR112023023775A2 (pt) 2021-05-14 2024-02-20 Genentech Inc Métodos para tratar um indivíduo com um distúrbio proliferativo de células positivas para cd20 e para tratar uma população de indivíduos com um distúrbio proliferativo de células positivas para cd20
WO2023057650A1 (fr) 2021-10-10 2023-04-13 Centre Hospitalier Universitaire Vaudois (Chuv) Procédé de prédiction d'effets secondaires de médicaments et de vaccins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
CA2326389C (fr) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Polypeptides specifiques a cd19 et cd3 et leurs utilisations
US20070224191A1 (en) 2002-12-05 2007-09-27 Pdl Biopharma, Inc. Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies
CA2522586C (fr) 2003-05-31 2017-02-21 Micromet Ag Compositions pharmaceutiques comprenant des constructions d'anticorps anti-cd3, anti-cd19 bispecifiques pour le traitement de troubles associes aux lymphocytes b
EP1874821B1 (fr) 2005-04-26 2013-04-17 Trion Pharma Gmbh Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
CA2633594C (fr) 2005-12-16 2021-10-26 Micromet Ag Moyens et procedes pour le traitement de maladies tumorales
KR101626988B1 (ko) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
EP2982696B1 (fr) * 2008-11-07 2019-03-27 Amgen Research (Munich) GmbH Traitement de la leucémie lymphoblastique aiguë
KR102406407B1 (ko) 2009-10-27 2022-06-08 암젠 리서치 (뮌헨) 게엠베하 ＣＤ１９ｘＣＤ３ 이중특이적 항체를 투여하는 투약 용법
WO2012055961A1 (fr) 2010-10-27 2012-05-03 Micromet Gmbh Moyens et méthodes de traitement du lymphome b diffus à grandes cellules
KR101891845B1 (ko) 2010-11-10 2018-08-24 암젠 리서치 (뮌헨) 게엠베하 Cd3-특이적 결합 도메인에 의해 유발된 악영향의 예방

Also Published As

Publication number Publication date
PL2637670T5 (pl) 2024-06-10
DK2637670T3 (en) 2017-06-19
CY1118894T1 (el) 2018-01-10
SI2637670T1 (sl) 2017-06-30
PH12013500940A1 (en) 2013-07-08
AU2017202079A1 (en) 2017-04-20
EP2637670B2 (fr) 2024-03-13
KR101891845B1 (ko) 2018-08-24
PT2637670T (pt) 2017-05-18
AU2018200915B2 (en) 2019-09-19
CN103533943B (zh) 2018-02-13
EA201390621A1 (ru) 2014-05-30
KR20140008313A (ko) 2014-01-21
NZ610034A (en) 2015-05-29
DK2637670T4 (da) 2024-03-25
HRP20170814T1 (hr) 2017-08-11
RS55995B1 (sr) 2017-09-29
EP3831386A1 (fr) 2021-06-09
JP6189491B2 (ja) 2017-08-30
SI2637670T2 (sl) 2024-06-28
CN103533943A (zh) 2014-01-22
SG10201508789TA (en) 2015-11-27
AU2011328393A1 (en) 2013-05-23
CL2013001287A1 (es) 2014-02-21
JP6023717B2 (ja) 2016-11-09
EA026075B1 (ru) 2017-02-28
IL226268B (en) 2018-02-28
UA113397C2 (xx) 2017-01-25
ES2627538T5 (es) 2024-12-02
CN108403702A (zh) 2018-08-17
SG190174A1 (en) 2013-07-31
AU2018200915A1 (en) 2018-03-01
US20130287774A1 (en) 2013-10-31
EP2637670B1 (fr) 2017-03-08
CR20130278A (es) 2013-09-20
US11633408B2 (en) 2023-04-25
CA2816668C (fr) 2021-03-23
JP2016193932A (ja) 2016-11-17
IL257164B (en) 2020-01-30
ES2627538T3 (es) 2017-07-28
ES2842937T3 (es) 2021-07-15
EP3228315B1 (fr) 2020-11-25
CA2816668A1 (fr) 2012-05-18
SMT201700250T1 (it) 2017-07-18
WO2012062596A1 (fr) 2012-05-18
US20190142846A1 (en) 2019-05-16
TN2013000250A1 (en) 2014-11-10
PL2637670T3 (pl) 2017-08-31
US10130638B2 (en) 2018-11-20
EP3228315A1 (fr) 2017-10-11
FI2637670T4 (fi) 2024-03-19
RS55995B2 (sr) 2024-04-30
EP2637670A1 (fr) 2013-09-18
HUE032782T2 (en) 2017-10-30
MY173177A (en) 2020-01-02
AU2017202079B2 (en) 2017-11-30
HRP20170814T4 (hr) 2024-05-10
JP2014504272A (ja) 2014-02-20
LT2637670T (lt) 2017-05-25
IL257164A (en) 2018-03-29
IL226268A0 (en) 2013-07-31
ME02722B (fr) 2017-10-20
AU2011328393B2 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
MA34726B1 (fr) Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3
MA40454B1 (fr) Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
FR2934782B1 (fr) Kit pour le traitement des onychomycoses.
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
CA2820681C (fr) Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
EA201301293A1 (ru) Применение антител и фрагментов антител против cgrp для профилактики или ингибирования светобоязни или отвращения к свету у субъектов, нуждающихся в этом, в особенности страдающих мигренью
MA33607B1 (fr) Molécules de liaison bispécifiques pour une thérapie anti-angiogénique
MX2020009260A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos.
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EP1796669A4 (fr) Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA30632B1 (fr) Anticorps humanisé
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
ATE503754T1 (de) 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
MA38478A1 (fr) Anticorps anti-pac1 humains
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
FR2959128B1 (fr) Utilisation cosmetique d'un lysat de bifidobacterium species pour le traitement des odeurs corporelles
FR3103706B1 (fr) Composition cosmétique triphasique
MA62935B1 (fr) Méthodes de traitement ou de prévention de l'amyotrophie spinale
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel